leisure time -WSS

leisure time

author：knowledge 2025-09-11 10:30:29 - browse：659

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Shifting the focus from loneliness to social health

WSS

How a Boston hospital is priming medical residents to use GPT

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Mystery swirls around US soldier who entered North Korea days ago, officials say

Letters to First Opinion on caregivers, digital health, and more

focus

leisure time

focus

After affirmative action ruling, medical educators look to 'holistic review'

Shifting the focus from loneliness to social health

23andMe had bad news about my health. I wish a person had delivered it

Letters to First Opinion on caregivers, digital health, and more

Drug repurposing or repositioning? The language matters

Hormonal contraceptives don’t actually treat endometriosis

Medicare details structure of new drug price negotiation program

Caribou posts encouraging results on off

Anesthesiologist group: stop taking Ozempic before surgery

Caribou posts encouraging results on off

Wikipedia

How to increase colonoscopy rates? Looks like an AI can help

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

NIH documents show early flaws of $1.6 billion long Covid program

How a Boston hospital is priming medical residents to use GPT

Intellia reports positive results for its CRISPR

Extensive review finds private equity owners jack up cost of care

leisure time

knowledge

leisure time

focus